Schering AG Bolsters MS Pipeline With Acquisition Of Celera Research Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Celera’s cathepsin S inhibitor program includes CRA-028129, now in Phase I, for treatment of autoimmune diseases.